Sign In
Buy GTHX
$7.15
+0 (+0%)
At Close: Dec 16, 2024
- Pivotal Program Evaluated the Effects of Administering COSELA Prior to Chemotherapy on Clinically Relevant Endpoints Across Multiple Hematopoietic Lineages, Including Hematologic Adverse Events, Lab
G1 Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
07:00am, Wednesday, 07'th Apr 2021
RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Baile
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 02'nd Apr 2021
RESEARCH TRIANGLE PARK, N.C., April 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerci
G1 Therapeutics to Host Virtual COSELA™ (trilaciclib) Kickoff Analyst and Investor Summit on April 9, 2021
07:30am, Thursday, 01'st Apr 2021
RESEARCH TRIANGLE PARK, N.C., April 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will host a virtual COSELA
COSELA Added to Both the NCCN Treatment Guidelines for Small Cell Lung Cancer and the NCCN Supportive Care Guidelines for Hematopoietic Growth Factors COSELA Added to Both the NCCN Treatment Guideline
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 05'th Mar 2021
RESEARCH TRIANGLE PARK, N.C., March 05, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerci
G1 Therapeutics to Participate in Two Investor Conferences in March
07:30am, Wednesday, 03'rd Mar 2021
RESEARCH TRIANGLE PARK, N.C., March 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two inv
G1 Therapeutics - Brighter Days Ahead
03:21pm, Tuesday, 02'nd Mar 2021
G1 Therapeutics' first in class drug, Myelosuppression drug, Cosela has blockbuster potential.
- Launch of Innovative Therapy for People Living with Extensive-Stage Small Cell Lung Cancer is Supported by the G1 to One™ Patient Support Program, the Single Source for COSELA Access Solutions - -
G1 Therapeutics' (GTHX) CEO Jack Bailey on Q4 2020 Results - Earnings Call Transcript
10:41pm, Wednesday, 24'th Feb 2021
G1 Therapeutics' (GTHX) CEO Jack Bailey on Q4 2020 Results - Earnings Call Transcript
Recap: G1 Therapeutics Q4 Earnings
05:23pm, Wednesday, 24'th Feb 2021
Shares of G1 Therapeutics (NASDAQ:GTHX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 28.72% year over year to ($0.67), which beat the
G1 Therapeutics Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
04:01pm, Wednesday, 24'th Feb 2021
- G1's COSELA™ (trilaciclib) Approved by FDA as First and Only Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression; Commercial Availability Expected in Early March -
G1 Therapeutics to Provide Fourth Quarter and Full Year 2020 Financial Results and Business Update on February 24, 2021
08:00am, Wednesday, 17'th Feb 2021
RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporat
G1 Therapeutics' Trilaciclib Wins FDA Nod For Mitigating Chemo Effects In Lung Cancer Patients
04:37am, Tuesday, 16'th Feb 2021
G1 Therapeutics Inc (NASDAQ: GTHX) shares gain premarket after FDA approves COSELA (trilaciclib) for injection to decrease the incidence of chemotherapy-induced myelosuppression (damage to bone ma
- COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy -
